Nahdi Medical Company
4164.SRSAUHealthcare● Active
$95.40
$-0.10(-0.10%)
Market Cap$12.4B
P/E Ratio—
52W High$132.1
52W Low$91
Nahdi Medical Company (4164.SR) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · 4164.SR · as of 2026-06-15
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.83B | $0.83B | $0.94B | $0.94B | $0.86B |
| Depreciation & Amort. | $0.78B | $0.70B | $0.62B | $0.60B | $0.57B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | ($0.55B) | ($0.01B) | ($0.16B) | $0.05B | ($0.01B) |
| Net Cash from Operations | $1.19B | $1.49B | $1.37B | $1.67B | $1.33B |
| Investing Activities | |||||
| Capital Expenditure | ($0.39B) | ($0.38B) | ($0.38B) | ($0.28B) | ($0.31B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.41B) | ($0.33B) | ($0.38B) | ($0.28B) | ($0.30B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | ($0.73B) | ($0.71B) | ($0.71B) | ($0.30B) | ($1.26B) |
| Debt Issued / Repaid | $0.00B | ($0.40B) | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | ($1.18B) | ($1.12B) | ($1.15B) | ($0.72B) | ($1.64B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.81B | $1.11B | $0.98B | $1.39B | $1.03B |
| FCF Margin %(computed) | 7.90% | 11.72% | 11.30% | 16.16% | 12.74% |
Data source: Financial Modeling Prep · Last updated: 2026-06-15 · SAR · B
Explore more Nahdi Medical Company data
About Nahdi Medical Company (4164.SR) Cash Flow Statement
Nahdi Medical Company generated operating cash flow of $1.19B and free cash flow of $0.81B for 2025 — a FCF margin of 7.90%. Capital expenditure was ($0.39B).
Frequently asked questions
4164.SR · 4 questionsNahdi Medical Company generated free cash flow of $0.81B for 2025, down 27.1% year-over-year.
4164.SR free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-15